Active substance
Phenoxymethylpenicillin
- SFDA 13
- US FDA 41
- Health Canada 1
- US price lines 6
- NHS prices 6
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| OSPEN 1000 | 1000000 IU | Tablet · Oral use | 30 Blister | SAR 27.40 | NCE · Prescription | SANDOZ | Valid |
| OSPEN 500 | 500000 IU | Tablet · Oral use | 30 Blister | SAR 21.25 | NCE · Prescription | SANDOZ | Valid |
| ORVEK SYP 125MG-5ML | 25 mg/ml | Syrup · Oral use | 1 Bottle | SAR 4.80 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| ORVEK-250 SYRUP(250MG-5ML) | 50 mg/ml | Syrup · Oral use | 1 Bottle | SAR 10.20 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| OSPEN 200 GRANULES FOR SUSP | 125 mg/ml | Powder for oral suspension · Oral use | 60 Bottle | SAR 14.90 | NCE · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| OSPEN 200 GRANULES FOR SUSP | 125 mg/ml | Powder for oral suspension · Oral use | 100 Bottle | SAR 18.05 | NCE · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| OSPEN 250MG TAB | 250 mg | Tablet · Oral use | 20 Blister | SAR 7.75 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| OSPEN 250MG-5ML ORAL SUSP | 50 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 27.40 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| OSPEN 400 GRANU.FOR SUSP | 50 mg/ml | Powder for oral suspension · Oral use | 60 Bottle | SAR 21.55 | NCE · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| V-CIL-K 250MG TAB | 250 mg | Tablet · Oral use | 24 Blister | SAR 4.15 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| VIKADAR FORTE TAB 1000000 I.U | 1000000 IU | Tablet · Oral use | 20 Blister | SAR 7.15 | Generic · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
| VIKADAR SUSP 200000 IU-5ML | 40000 IU/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 4.75 | Generic · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
| VIKADAR TAB 500000 I.U | 500000 IU | Tablet · Oral use | 20 Blister | SAR 4.50 | Generic · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANTIMICROBIAL PROPHYLAXIS IN CANCER PATIENTS; BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; DENTAL ABSCESS; NECROTIZING PERIODONTITIS AND NECROTIZING ULCERATIVE GINGIVITIS; PERICORONITIS; PHARYNGITIS; PREVENTION AND CHEMOPROPHYLAXIS OF BACTERIAL MENINGITIS- MENINGITIS, MENINGOCOCCAL INFECTIONS PREVENTION (CHEMOPROPHYLAXIS); RENAL TRANSPLANT; TRAVEL RELATED INFECTIONS-TREATMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PENICILLIN-VK | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | CHARTWELL RX | Prescription | 3 Jul 1968 |
| PENICILLIN-VK | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | CHARTWELL RX | Prescription | 31 Jul 1968 |
| PENICILLIN V POTASSIUM | EQ 500MG BASE | tablet · oral | CHARTWELL RX | Prescription | 23 Nov 1988 |
| PENICILLIN V POTASSIUM | EQ 250MG BASE | tablet · oral | CHARTWELL RX | Prescription | 25 Nov 1988 |
| PENICILLIN V POTASSIUM | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | AUROBINDO PHARMA | Prescription | 29 Apr 2008 |
| PENICILLIN V POTASSIUM | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | HIKMA PHARMS | Prescription | 11 Oct 2013 |
| PEN-VEE K | EQ 125MG BASE; EQ 250MG BASE; EQ 500MG BASE | tablet · oral | WYETH AYERST | Discontinued | 13 Jan 1958 |
| V-CILLIN K | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | LILLY | Discontinued | 7 Apr 1967 |
| VEETIDS | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | APOTHECON | Discontinued | 8 Mar 1971 |
| PENICILLIN V POTASSIUM | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | BELCHER PHARMS | Discontinued | 17 Nov 1971 |
| PENICILLIN V POTASSIUM | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | BELCHER PHARMS | Discontinued | 18 Nov 1971 |
| PENICILLIN V POTASSIUM | EQ 250MG BASE/5ML; EQ 125MG BASE/5ML | for solution · oral | MYLAN | Discontinued | 7 Aug 1972 |
| PFIZERPEN VK | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | PFIZER | Discontinued | 9 Aug 1974 |
| PFIZERPEN VK | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | PFIZER | Discontinued | 14 Nov 1974 |
| PENICILLIN V POTASSIUM | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | PUREPAC PHARM | Discontinued | 28 Oct 1976 |
| BEEPEN-VK | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | GLAXOSMITHKLINE | Discontinued | 12 Aug 1980 |
| BEEPEN-VK | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | GLAXOSMITHKLINE | Discontinued | 15 Aug 1980 |
| PENICILLIN V POTASSIUM | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | CHARTWELL RX | Discontinued | 10 Feb 1989 |
| PENICILLIN V POTASSIUM | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | SANDOZ | Discontinued | 30 Nov 1995 |
| VEETIDS | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | APOTHECON | Discontinued | 7 Dec 2007 |
| V-CILLIN | 125MG/0.6ML | for suspension · oral | LILLY | Discontinued | |
| V-CILLIN K | EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | LILLY | Discontinued | |
| PEN-VEE K | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | WYETH AYERST | Discontinued | |
| LEDERCILLIN VK | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | LEDERLE | Discontinued | |
| LEDERCILLIN VK | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for solution · oral | LEDERLE | Discontinued |
16 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PEN-VK | 00642215 | 300 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PENICILLIN VK 125 MG/5 ML SOLN | $0.07771 | per ML | 23 Sep 2026 |
| US NADAC | PENICILLIN VK 125 MG/5 ML SOLN | $0.04987 | per ML | 23 Sep 2026 |
| US NADAC | PENICILLIN VK 250 MG TABLET | $0.06082 | per EA | 23 Sep 2026 |
| US NADAC | PENICILLIN VK 250 MG/5 ML SOLN | $0.05897 | per ML | 23 Sep 2026 |
| US NADAC | PENICILLIN VK 250 MG/5 ML SOLN | $0.0443 | per ML | 23 Sep 2026 |
| US NADAC | PENICILLIN VK 500 MG TABLET | $0.09847 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Phenoxymethylpenicillin 125mg/5ml oral solution | £1.62 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Phenoxymethylpenicillin 125mg/5ml oral solution sugar free | £2.28 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Phenoxymethylpenicillin 250mg tablets | £1.16 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Phenoxymethylpenicillin 250mg/5ml oral solution | £2.22 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Phenoxymethylpenicillin 250mg/5ml oral solution sugar free | £2.07 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Phenoxymethylpenicillin 500mg tablets | £3.99 | 20 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.1. Access group antibiotics · core
First choice: Bacterial pneumonia (Community-acquired pneumonia - mild to moderate); First choice: Periapical abscess without sinus; First choice: Acute pharyngitis
Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid | Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt) (EML)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.